OSAKA (AP) — Japanese pharmaceutical maker Shionogi hopes to be able to sell its COVID-19 drug Xocova in the United States by early 2025, focusing on overseas sales as government investment in coronavirus drugs in Japan ends this month.
If the review through the U. S. Food and Drug Administration will not be required. As the U. S. moves smoothly and the anti-Covid tablet is launched, “the review procedure will also be accelerated in other countries,” Shionogi CEO Isao Teshirogi told Nikkei on Tuesday.